Black Diamond Therapeutics, Inc. (BDTX) 2024年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549_FORM 10-K_ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE FISCAL YEAR ENDED December 31,2024OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE

2、ACT OF 1934FOR THE TRANSITION PERIOD FROM _ TO _COMMISSION FILE NUMBER 001-38501_BLACK DIAMOND THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)_Delaware81-4254660(State or other jurisdictionof incorporation or organization)(I.R.S.EmployerIdentification No.)One Main Street,14th

3、 FloorCambridge,Massachusetts(Address of principal executive offices)02142(Zip Code)(617)252-0848(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon stock,par v

4、alue$0.0001BDTXThe Nasdaq Global Select Market _Securities registered pursuant to Section 12(g)of the Act:None.Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file

5、 reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was r

6、equired to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(232.405 of this chapter)du